uracil has been researched along with Diarrhea in 41 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 9.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "Eniluracil/5-FU as a 28-day oral outpatient regimen is well tolerated by patients with inoperable hepatocellular carcinoma, although minimal activity was observed when given as monotherapy at the dose used in this study." | 9.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 9.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 6.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 5.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)." | 5.11 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004) |
| "Eniluracil/5-FU as a 28-day oral outpatient regimen is well tolerated by patients with inoperable hepatocellular carcinoma, although minimal activity was observed when given as monotherapy at the dose used in this study." | 5.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| " Diarrhea was the principal dose-limiting toxicity of oral 5-FU and eniluracil given on this chronic schedule." | 5.09 | Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ( Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 5.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | 3.69 | Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| " Adverse events occurred in 151 (72." | 2.82 | Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. ( Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 2.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| " The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump." | 2.69 | A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000) |
| "Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms." | 2.68 | The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group. ( Belón, J; de Castro, J; Espinosa, E; Feliu, J; García Alfonso, P; García Girón, C; Garrido, P; González Barón, M; Lomas, M; Ordóñez, A; Zamora, P, 1997) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| "Fifty-one patients with metastatic colorectal cancer were enrolled in the study." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| " Pharmacokinetic examination after intravenous injection of low-dose MMC (0." | 1.29 | A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (41.46) | 18.2507 |
| 2000's | 18 (43.90) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison, SA | 1 |
| Bashir, MR | 1 |
| Guy, CD | 1 |
| Zhou, R | 1 |
| Moylan, CA | 1 |
| Frias, JP | 1 |
| Alkhouri, N | 1 |
| Bansal, MB | 1 |
| Baum, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Taub, R | 1 |
| Moussa, SE | 1 |
| Flisiak, R | 1 |
| Janczewska, E | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Jaroszewicz, J | 1 |
| Zarębska-Michaluk, D | 1 |
| Nazzal, K | 1 |
| Bolewska, B | 1 |
| Bialkowska, J | 1 |
| Berak, H | 1 |
| Fleischer-Stępniewska, K | 1 |
| Tomasiewicz, K | 1 |
| Karwowska, K | 1 |
| Rostkowska, K | 1 |
| Piekarska, A | 1 |
| Tronina, O | 1 |
| Madej, G | 1 |
| Garlicki, A | 1 |
| Lucejko, M | 1 |
| Pisula, A | 1 |
| Karpińska, E | 1 |
| Kryczka, W | 1 |
| Wiercińska-Drapało, A | 1 |
| Mozer-Lisewska, I | 1 |
| Jabłkowski, M | 1 |
| Horban, A | 1 |
| Knysz, B | 1 |
| Tudrujek, M | 1 |
| Halota, W | 1 |
| Simon, K | 1 |
| Bin, Q | 1 |
| Li, J | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Hsu, CH | 1 |
| Shen, YC | 1 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 1 |
| Ding, YH | 1 |
| Hsu, C | 1 |
| Cheng, AL | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 1 |
| Watanabe, M | 1 |
| Wettergren, Y | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Rothenberg, ML | 1 |
| Benedetti, JK | 1 |
| Macdonald, JS | 1 |
| Seay, TE | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Abbruzzese, JL | 2 |
| Yang, TS | 1 |
| Wang, JY | 1 |
| Tang, R | 1 |
| Hsu, KC | 1 |
| Chen, JS | 1 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Sakuyama, T | 1 |
| Yokoyama, M | 1 |
| Ogawa, M | 1 |
| Takao, Y | 1 |
| Sato, K | 1 |
| Kawahara, H | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Hirai, K | 1 |
| Feliu, J | 3 |
| Vicent, JM | 1 |
| García-Girón, C | 1 |
| Constela, M | 1 |
| Fonseca, E | 1 |
| Aparicio, J | 1 |
| Lomas, M | 2 |
| Antón-Aparicio, L | 1 |
| Dorta, FJ | 1 |
| Gonzalez-Baron, M | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Yamaguchi, K | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 1 |
| Pfeiffer, P | 2 |
| Bennouna, J | 2 |
| Perrier, H | 1 |
| Paillot, B | 1 |
| Priou, F | 1 |
| Jacob, JH | 1 |
| Hebbar, M | 1 |
| Bordenave, S | 1 |
| Seitz, JF | 1 |
| Cvitkovic, F | 1 |
| Dorval, E | 1 |
| Malek, K | 1 |
| Tonelli, D | 1 |
| Douillard, JY | 2 |
| Sato, Y | 1 |
| Inaba, Y | 1 |
| Yamaura, H | 1 |
| Shimamoto, H | 1 |
| Nishiofuku, H | 1 |
| Oyama, T | 1 |
| Kanemitsu, Y | 1 |
| Sawaki, A | 1 |
| Arai, Y | 1 |
| Muro, K | 2 |
| Mizushima, T | 1 |
| Mizuno, H | 1 |
| Ito, T | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Iwamoto, T | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Etienne-Grimaldi, MC | 1 |
| François, E | 1 |
| Cardot, JM | 1 |
| Renée, N | 1 |
| Gamelin, E | 1 |
| Château, Y | 1 |
| Milano, G | 1 |
| Saltz, LB | 1 |
| Leichman, CG | 2 |
| Young, CW | 1 |
| Muggia, FM | 2 |
| Conti, JA | 1 |
| Spiess, T | 1 |
| Jeffers, S | 2 |
| Leichman, LP | 1 |
| Pazdur, R | 1 |
| Lassere, Y | 1 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Bready, B | 1 |
| Daniels, M | 1 |
| Díaz-Rubio, E | 4 |
| Guillem, V | 1 |
| Montero, JM | 1 |
| García-Conde, J | 1 |
| Estapé, J | 1 |
| Martín, M | 2 |
| Herranz, C | 1 |
| Ordoñez, A | 2 |
| Galán, A | 1 |
| Boku, N | 1 |
| Ohtsu, A | 1 |
| Kaneko, K | 1 |
| Muto, M | 1 |
| Ohkuwa, M | 1 |
| Ishii, H | 1 |
| Sasaki, Y | 1 |
| Tajiri, H | 1 |
| Yoshida, S | 1 |
| Kusada, O | 1 |
| González Barón, M | 2 |
| Espinosa, E | 2 |
| García Girón, C | 2 |
| de la Gándara, I | 1 |
| Espinosa, J | 1 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| de Castro, J | 2 |
| Kurokawa, H | 1 |
| Miura, K | 1 |
| Yamashita, Y | 1 |
| Tokudome, S | 1 |
| Murata, T | 1 |
| Kajiyama, M | 1 |
| Abad, A | 1 |
| Navarro, M | 1 |
| Sastre, J | 1 |
| Marcuello, E | 1 |
| Aranda, E | 1 |
| Gallén, M | 1 |
| Fernandez-Martos, C | 1 |
| Martín, C | 1 |
| Casado, A | 1 |
| López-Martin, JA | 1 |
| Rodriguez-Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Zamora, P | 1 |
| García Alfonso, P | 1 |
| Garrido, P | 1 |
| Belón, J | 1 |
| Kurihara, M | 1 |
| Kim, YH | 1 |
| Shin, SW | 1 |
| Kim, BS | 1 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Kim, JS | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Leichman, L | 1 |
| Chan, KK | 1 |
| Johnson, MR | 1 |
| Hageboutros, A | 1 |
| Wang, K | 1 |
| High, L | 1 |
| Smith, JB | 1 |
| Diasio, RB | 2 |
| de la Torre, A | 1 |
| Ramos, S | 1 |
| Valcárcel, FJ | 1 |
| Candal, A | 1 |
| Regueiro, CA | 1 |
| Romero, J | 1 |
| Magallón, R | 1 |
| Salinas, J | 1 |
| de las Heras, M | 1 |
| Veiras, C | 1 |
| Tisaire, JL | 1 |
| Aragón, G | 1 |
| Baker, SD | 1 |
| O'Reilly, S | 1 |
| Lucas, VS | 1 |
| Khor, SP | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Spector, T | 1 |
| Hohneker, JA | 1 |
| Rowinsky, EK | 1 |
| Childs, HA | 1 |
| Spencer, SA | 1 |
| Raben, D | 1 |
| Bonner, JA | 1 |
| Newsome, J | 1 |
| Robert, F | 1 |
| Bokemeyer, C | 1 |
| Hartmann, JT | 1 |
| Mayer, F | 1 |
| Böhlke, I | 1 |
| Kanz, L | 1 |
| Von Pawel, J | 1 |
| Derigs, G | 1 |
| Schröder, M | 1 |
| Alonso, V | 1 |
| Escudero, P | 1 |
| Zorrilla, M | 1 |
| Isla, MD | 1 |
| Herrero, A | 1 |
| Mayordomo, JI | 1 |
| Martinez-Trufero, J | 1 |
| Sáenz, A | 1 |
| Tres, A | 1 |
| Antón, A | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Sinlarat, P | 1 |
| Lohsiriwat, D | 1 |
| Lert-Akayamanee, N | 1 |
| Nimmanwudipong, T | 1 |
| Srimuninnimit, V | 1 |
| Vathanophas, V | 1 |
| Arch-Yaemsuan, P | 1 |
| Boonnuch, W | 1 |
| Benson, AB | 1 |
| Mitchell, E | 1 |
| Abramson, N | 1 |
| Klencke, B | 1 |
| Ritch, P | 1 |
| Burnhan, JP | 1 |
| McGuirt, C | 1 |
| Bonny, T | 1 |
| Levin, J | 1 |
| Hohneker, J | 1 |
| Adimi, P | 1 |
| Hansen, F | 1 |
| Kjaer, M | 1 |
| Aabo, K | 1 |
| Keldsen, N | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Ohyama, M | 1 |
| Matsumura, M | 1 |
| Katsuta, K | 1 |
| Nobori, T | 1 |
| Matsuyama, H | 1 |
| Fukami, K | 1 |
| Kiyota, R | 1 |
| Yano, H | 1 |
| Shima, T | 1 |
| Ogawa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection[NCT04369807] | 693 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis[NCT02912260] | Phase 2 | 125 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers[NCT05921006] | Phase 1 | 98 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine[NCT06083636] | 500 participants (Anticipated) | Observational | 2022-07-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uracil and Diarrhea
| Article | Year |
|---|---|
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
29 trials available for uracil and Diarrhea
| Article | Year |
|---|---|
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therap | 2016 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad | 2004 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Color | 1995 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
Phase II trial of UFT activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A | 1993 |
[Evaluation of neo-adjuvant chemotherapy for oral squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
Topics: Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Etop | 1997 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Diarrhea; Disease-Free S | 1999 |
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineo | 2000 |
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Re | 2000 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coh | 2001 |
Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; | 2001 |
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
11 other studies available for uracil and Diarrhea
| Article | Year |
|---|---|
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Diseas | 1996 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea | 1997 |
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Basal Cell; Diarrhea; Dihydrour | 1999 |
[A comparative study of UFT enteric-coated granules with UFT capsules on the occurrence of side effects in patients with head and neck cancers--a special attention to the upper gastrointestinal tract disorders].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capsules; Diarrhea; | 1990 |